You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ):全資子公司獲得瑞巴派特片藥品註冊證書
格隆匯 06-28 19:37

格隆匯6月28日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東華南藥業集團有限公司於近日收到國家藥品監督管理局核准簽發的瑞巴派特片《藥品註冊證書》。

瑞巴派特片是一種胃黏膜保護劑,具有保護胃黏膜及促進潰瘍癒合的作用。瑞巴派特片為醫保目錄乙類藥物,臨牀用於急性胃炎、慢性胃炎的急性加重期胃黏膜病變(糜爛、出血、充血、水腫)的改善,以及用於胃潰瘍的治療。

根據米內網數據庫顯示,瑞巴派特片2021至2023年在中國城市公立醫院及中國城市實體藥店的銷售總額合計為人民幣72,854萬元,75,044萬元,81,192萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account